Wall Street analysts have crafted a short list of companies most likely to acquire Celgene's anti-inflammation drug Otezla, with top names including Gilead, Amgen and Johnson & Johnson. Gilead has its ...
MyoKardia will spend up to $80 million to buy back U.S. royalty rights on mavacamten and MYK-224 from Sanofi, the last economic tie the two companies have retained since the French big pharma ended ...
Strong performance in the second quarter spurred Novartis to raise its sales and profit forecasts for the year, sending shares in the drugmaker to near five-year highs on Thursday. Company executives, ...
Advocacy group Patients For Affordable Drugs said it has made a "six-figure" ad purchase to press for the Trump administration's plan to link Medicare reimbursement to overseas prices for certain ...
AbbVie has expanded its oncology pipeline with the acquisition of Mavupharma, a privately held biotech targeting cancer ...
Johnson & Johnson reported sales of blood thinner Xarelto fell 19% to $549 million in the second quarter of 2019 compared ...
Inovio Pharmaceuticals will lay off approximately 80 employees, cut back on spending and drop several research programs in an effort to extend the time it can fund operations. Most notably, a Phase ...
An executive shake-up appears to be part of the plan as O'Day begins his work in turning around Gilead, which has seen its revenue sharply drop as sales from its hepatitis C drugs have declined for ...
The Food and Drug Administration on Wednesday approved Merck & Co.'s triple antibacterial Recarbrio for treatment of complicated urinary tract and abdominal infections caused by one of 16 different ...
While the Trump administration's drug pricing plans have stalled in recent weeks, several Democratic presidential hopefuls have rolled out their own plans to curb rising pharmaceutical costs, poised ...
Sickle cell disease is one of the most common genetic blood disorders, but treatment options have been mostly limited to blood transfusions and hydroxyurea, a decades-old myelosuppressive drug. While ...
Recent news and headlines have been saturated with stories about data security and consumer privacy. In the healthcare industry especially, the heightened privacy focus, new policies from ...